Trodelvy（sacituzumab govitecan-hziy）（抗原浓缩液）说明书 Trodelvy™ (sacituzumab govitecan-hziy)(Intravenous)Document Number: IC-0532 Last Review Date: 01/01/2021 Date of Origin: 06/02/2020 Dates Reviewed: 06/2020, 09/2020, 01/2021 I.Length of Authorization Coverage will be provided ...
简要标题 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer 临床分期 Phase 3 招募状态 Active, not recruiting 首次公开日期 2020-10-20 条件/疾病 Triple Negative Breast Cancer | HER2-negative Breast Cancer 干预/治疗 Sacituzumab govitecan | Capecitabine | Carboplatin | Cisplatin 申办方 Germa...
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.doi:10.1200/JCO.2023.41.16_suppl.4572221114572#Background:SG is an antibody-drug conjugate (ADC) with ...
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clin. Cancer Res. 2021, 27, 1850–1854. [Google Scholar] [CrossRef] Bardia, A.; Mayer, I.A.; Vahdat, L.T.; Tolaney, S.M.; Isakoff, S.J....